尿路上皮癌术中应用羟喜树碱创面灌注化疗导致急性骨髓抑制的患者的特征及预防  

Characteristics and prevention of acute myelosuppression in patients with urothelial carcinoma treated with hydroxycamptothecin infusion chemotherapy

作　　者：王艳龙 杜浩 任宇 王伟 于广海 Wang Yanlong;Du Hao;Ren Yu;Wang Wei;Yu Guanghai(Department of Urology,Dalian Central Hospital,Dalian Medical University,Dalian 116033,China)

机构地区：[1]大连医科大学附属大连市中心医院泌尿外科,116033

出　　处：《国际医药卫生导报》2019年第21期3581-3584,共4页International Medicine and Health Guidance News

摘　　要：目的分析羟喜树碱用于尿路上皮癌患者术后出现急性骨髓抑制的患者的特征及预防.方法收集56例尿路上皮癌患者的临床资料,所有患者术中均应用羟喜树碱行创面灌注.结果术后发生急性骨髓抑制比例为7.1%(4/56),所有患者经过积极的升白细胞、补充血小板、输红细胞、促进造血等治疗后均恢复正常,没有严重并发症发生.结论对于高龄、合并高血压或糖尿病、身体免疫力低下的尿路上皮癌患者,术中应用羟喜树碱创面灌注化疗应权衡利弊,避免发生急性骨髓抑制的发生.Objective To analyze the characteristics and prevention of acute myelosuppression in patients with urothelial carcinoma after treatment with hydroxycamptothecin.Methods The clinical data of 56 patients with urothelial carcinoma were collected.All the patients underwent intraoperative perfusion with hydroxycamptothecin.Results The rate of acute myelosuppression occurred after surgery was 7.1%(4/56).All the patients returned to normal after positive leukopenia,platelet supplementation,red blood cell transfusion,and hematopoiesis.No serious complications occurred.Conclusions For elderly patients with urothelial carcinoma with hypertension or diabetes and low body immunity,while taking intraoperative hydroxycamptothecin infusion chemotherapy,the pros and cons should be weighed to avoid the occurrence of acute myelosuppression.

关 键 词：尿路上皮癌 羟喜树碱 急性骨髓抑制 

分 类 号：R73[医药卫生—肿瘤]